在高级表皮生长因子受体驱动的非小细胞肺癌中的新治疗策略:超越单剂奥西默蒂尼布
Paolo Maione1, Valentina Palma2, Giuseppina Pucillo2
1Division of Medical Oncology, S.G. Moscati Hospital, 83100 Avellino, Italy.
结合化疗或新型疗法与奥西默蒂尼布的新型肺癌治疗方法,改善了EGFR驱动的高级非小细胞肺癌 (NSCLC) 患者的无进展生存率,提供了超越标准护理的新希望.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
背景情况:
- 奥西默提尼布是先进的表皮生长因子受体 (EGFR) 驱动的非小细胞肺癌 (NSCLC) 的既定标准.
- 尽管它有效,但在改善治疗结果和无进展生存 (PFS) 方面仍然存在挑战.
研究的目的:
- 审查新兴的治疗策略,旨在在EGFR驱动的高级NSCLC中超越奥西默提尼布的疗效.
- 讨论评估新型组合疗法的最近临床试验的发现.
主要方法:
- 对包括FLAURA 2和MARIPOSA在内的III期随机试验的审查.
- 对治疗结果的分析,将新组合与单剂 osimertinib 进行比较.
主要成果:
- 基于的化疗和奥西默蒂尼布的组合显示出显著的PFS益处 (FLAURA 2试验).
- 与奥西默蒂尼布 (MARIPOSA研究) 相比,阿米万塔马布加拉泽提尼布显示出显著的PFS益处.
结论:
- 组合疗法代表了对EGFR驱动的先进NSCLC有前途的新治疗选择.
- 对个性化治疗策略的患者选择标准需要进一步研究.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
